Kali-Extracts Announces Developing Cannabis Pain Management Treatment For $83 Billion Market Specifically Targeting Cancer
April 04 2019 - 9:37AM
InvestorsHub NewsWire
Kali-Extracts Announces Developing
Cannabis Pain Management Treatment For $83 Billion Market
Specifically Targeting Cancer
Dallas, TX -- April 4, 2019 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced its ongoing research and
development of a cannabis pain management treatment derived from
the company’s patented cannabis extraction process. While
cannabis for pain management treatment from cancer is not new, KALY
is developing a proprietary extract that improves upon the cannabis
treatments currently approved by the FDA. The FDA approved a marijuana treatment for aiding in
the management of cancer symptoms and the side effects of other
cancer treatments in1985. That drug, marinol, is a synthetic form
of the marijuana cannabinoid THC and is used to treat both
chemotherapy-induced nausea and HIV-related weight loss. The
market for generic marinol is approximately $300 million per
year. KALY’s cannabis extract is not a synthetic. The
overall pain management treatment market is anticipated to reach
$83 billion by 2024.
Earlier this week, KALY announced
its ongoing research and development of a cannabis treatment for
Type 2 Diabetes. Kali-Extracts, through its patented cannabis
extraction process, is developing a variety of treatments for
various health issues. KALY recently published a research
report on its pilot cannabis treatment
for Chronic Obstructive Pulmonary Disease (COPD). KALY
is currently in the progress of beginning to disclose its
additional research and development of cannabis extracts for
additional health issues. The company currently has ongoing
cannabis extract research and development targeting four specific
health issues, COPD, Type 2 Diabetes, Cancer Pain Management and
one additional health issue KALY plans to announce next week
leading up to an online presentation with more detail on each of
the treatment developments later this month. The market for
Type 2 Diabetes is expected to be a $64 billion market by 2026. The market
for COPD treatment is anticipated to reach $14 billion by 2025. Beyond the four specific
cannabis therapies currently in various stages of research and
development, KALY has a number of additional target therapies in
its research pipeline.
In addition to its pharmaceutical
developments, KALY is generating revenue from is patented cannabis
extraction process delivering proprietary extracts for infusion
into non-pharmaceutical commercial products. KALY announced
last week finalizing it’s all new 25 mg CBD Extract formulation for
beverage infusion. KALY’s patented extraction process already
produces a 10 mg CBD formulation for Puration, Inc.’s (USOTC:
PURA) (“PURA”) leading EVERx CBD Sports Water. KALY has
also recently announced plans to provide commercial extraction for
Nouveau, Inc. (USOTC:
NOUV) (“NOUV”) in conjunction with NOUV’s recently announced
100-acre hemp farm.
KALY is
a health and wellness company set to generate revenue from its
patented cannabis extraction technology through overlapping
go-to-market strategies. In addition developing
pharmaceutical products internally and through partnerships, KALY
is utilizing is patented cannabis extraction process to develop
numerous wellness products both internally and through
partnerships. The first revenue generating contracts signed in
December of 2018 will be reflected in the company’s upcoming annual
report.
To learn more about the company
visit https://www.kali-extracts.com/
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024